Roche announced that detailed results from the evERA Breast Cancer study, showing investigational giredestrant in combination with everolimus significantly improved progression-free survival (PFS) ...
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy p ...
Danish drugmaker Lundbeck explores acquisition of Xeris Biopharma, sending Xeris shares to 2019 highs as markets react to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results